Risk of major cardiovascular events in adult patients with psoriasis treated with biologic therapies or methotrexate: Cohort study in the British Association of Dermatologists Biologic Interventions Register (BADBIR)

Rungapiromnan, W.; Mason, K.J.; Lunt, M.; McElhone, K.; Burden, A.D.; Rutter, M.K.; Warren, R.B.; Griffiths, C.E.M.; Ashcroft, D.M.; Study Group, BADBIR

doi:10.1111/jdv.16018

P181 Musculoskeletal pain and prognosis of acute coronary syndrome and cerebrovascular accident: a linked electronic health record cohort study (2022)
Journal Article
Mason, K. J., Jordan, K. P., Achana, F. A., Bailey, J., Chen, Y., Frisher, M., …Edwards, J. J. (2022). P181 Musculoskeletal pain and prognosis of acute coronary syndrome and cerebrovascular accident: a linked electronic health record cohort study. Rheumatology, 61(S1), https://doi.org/10.1093/rheumatology/keac133.180

Abstract Background/Aims There is some evidence of an increased risk of cardiovascular disease in patients with painful musculoskeletal conditions, but it is unclear if musculoskeletal pain also worsens its prognosis. The aim was to determine whethe... Read More about P181 Musculoskeletal pain and prognosis of acute coronary syndrome and cerebrovascular accident: a linked electronic health record cohort study.

HLA-C*06:02 allele is associated with higher drug survival in patients with psoriasis on ustekinumab: an analysis from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR), on behalf of the BADBIR and BSTOP study groups (2022)
Journal Article
Alabas, O., Mason, K., Yiu, Z., Warren, R., Dand, N., Barker, J., …Griffiths, C. (2022). HLA-C*06:02 allele is associated with higher drug survival in patients with psoriasis on ustekinumab: an analysis from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR), on behalf of the BADBIR and BSTOP study groups. British Journal of Dermatology, 186(1), e8-e9

Musculoskeletal pain and its impact on prognosis following hospitalisation for acute coronary syndrome or cerebrovascular accident: a linked electronic health record cohort study (MSKCOM) (2021)
Presentation / Conference
Mallen, Mason, Frisher, Mamas, Jordan, Marshall, …White. (2021, November). Musculoskeletal pain and its impact on prognosis following hospitalisation for acute coronary syndrome or cerebrovascular accident: a linked electronic health record cohort study (MSKCOM). Presented at SAPC North 2021, Virtual

Background: There is evidence that painful musculoskeletal conditions are associated with increased risk of cardiovascular disease, but less is known about whether this impacts on prognosis of cardiovascular disease. The aim was to determine whether... Read More about Musculoskeletal pain and its impact on prognosis following hospitalisation for acute coronary syndrome or cerebrovascular accident: a linked electronic health record cohort study (MSKCOM).

Musculoskeletal pain and its impact on prognosis following hospitalisation for acute coronary syndrome or cerebrovascular accident: a linked electronic health record cohort study (MSKCOM) (2021)
Presentation / Conference
Mason, K., Jordan, K. P., Achana, F., Bailey, J., Chen, Y., Frisher, M., …Edwards, J. J. (2021, November). Musculoskeletal pain and its impact on prognosis following hospitalisation for acute coronary syndrome or cerebrovascular accident: a linked electronic health record cohort study (MSKCOM). Paper presented at 2021 SAPC North, Virtual

Background: There is evidence that painful musculoskeletal conditions are associated with increased risk of cardiovascular disease, but less is known about whether this impacts on prognosis of cardiovascular disease. The aim was to determine whether... Read More about Musculoskeletal pain and its impact on prognosis following hospitalisation for acute coronary syndrome or cerebrovascular accident: a linked electronic health record cohort study (MSKCOM).

Musculoskeletal pain and its impact on prognosis following hospitalisation for acute coronary syndrome or cerebrovascular accident: a linked electronic health record cohort study (MSKCOM) (2021)
Presentation / Conference
Mason, K., Jordan, K., Achana, F., Bailey, J., Chen, Y., Frisher, M., …Edwards, J. (2021, November). Musculoskeletal pain and its impact on prognosis following hospitalisation for acute coronary syndrome or cerebrovascular accident: a linked electronic health record cohort study (MSKCOM). Poster presented at 2021 SAPC North, Virtual

Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey. (2021)
Journal Article
Mahil, S., Yates, M., Langan, S., Yiu, Z., Tsakok, T., Dand, N., …study groups, P. C. (2021). Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey. British Journal of Dermatology, 185(1), https://doi.org/10.1111/bjd.19755

BACKGROUND: Registry data suggest that people with immune-mediated inflammatory diseases (IMIDs) receiving targeted systemic therapies have fewer adverse coronavirus disease 2019 (COVID-19) outcomes compared with patients receiving no systemic treatm... Read More about Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey..

Describing the burden of the COVID-19 pandemic in people with psoriasis: findings from a global cross-sectional study. (2021)
Journal Article
Mahil, S., Yates, M., Yiu, Z., Langan, S., Tsakok, T., Dand, N., …Smith, C. (2021). Describing the burden of the COVID-19 pandemic in people with psoriasis: findings from a global cross-sectional study. Journal of the European Academy of Dermatology and Venereology, 35(10), e636-e640. https://doi.org/10.1111/jdv.17450

Indirect excess morbidity in the COVID-19 pandemic may arise from public health risk-mitigation efforts such as stay-at-home orders and re-purposing of healthcare services1 . Increased mental health disorders and shortfalls in the care of long-term c... Read More about Describing the burden of the COVID-19 pandemic in people with psoriasis: findings from a global cross-sectional study..

Describing the burden of the COVID-19 pandemic in people with psoriasis: findings from a global cross-sectional study (2021)
Other
Mahil, S., Yates, M., Yiu, Z., Langan, S., Tsakok, T., Dand, N., …Smith, C. Describing the burden of the COVID-19 pandemic in people with psoriasis: findings from a global cross-sectional study. [Preprint]

Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic vs non-biologic systemic therapies (2021)
Journal Article
Mason, K., Burden, A., Barker, J., Lunt, M., Ali, H., Kleyn, C., …Study Group, B. (2021). Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic vs non-biologic systemic therapies. Journal of the European Academy of Dermatology and Venereology, 35(8), https://doi.org/10.1111/jdv.17282

'No abstract'

Characteristics and skin cancer risk of psoriasis patients with a history of skin cancer in BADBIR (2021)
Journal Article
Mason, K., Burden, A., Barker, J., Lunt, M., Ali, H., Kleyn, C., …Study Group, T. B. (2021). Characteristics and skin cancer risk of psoriasis patients with a history of skin cancer in BADBIR. Journal of the European Academy of Dermatology and Venereology, 35(8), https://doi.org/10.1111/jdv.17230

The British Association of Dermatologists Biologics and Immunomodulators Register: a centenary celebration of research collaboration in British dermatology (2020)
Journal Article
Yiu, Z., Mason, K., Smith, C., Griffiths, C., & Study Group, B. (2020). The British Association of Dermatologists Biologics and Immunomodulators Register: a centenary celebration of research collaboration in British dermatology. British Journal of Dermatology, 183(6), 981-983. https://doi.org/10.1111/bjd.19536

The coronavirus disease 2019 (COVID‐19) pandemic has led to unexpected challenges and adversity in the centenary year of the British Association of Dermatologists (BAD). However, through challenge comes opportunity. Two national organizations were bo... Read More about The British Association of Dermatologists Biologics and Immunomodulators Register: a centenary celebration of research collaboration in British dermatology.

Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register. (2020)
Journal Article
Iskandar, I., Warren, R., Lunt, M., Mason, K., Evans, I., McElhone, K., …Ashcroft, D. (2020). Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register. JAMA Dermatology, 157(1), 66-73. https://doi.org/10.1001/jamadermatol.2020.4202

Importance: Treatments for psoriasis may be less effective in everyday practice than in clinical trials. Emulating a target trial using data from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) can provide t... Read More about Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register..

Factors associated with adverse COVID-19 outcomes in patients with psoriasis: insights from a global registry-based study (2020)
Journal Article
Mahil, S. K., Dand, N., Mason, K. J., Yiu, Z. Z. . N., Tsakok, T., Meynell, F., …study group, P. (2021). Factors associated with adverse COVID-19 outcomes in patients with psoriasis: insights from a global registry-based study. Journal of Allergy and Clinical Immunology, 147(1), 60-71. https://doi.org/10.1016/j.jaci.2020.10.007

BACKGROUND: The multi-morbid burden and use of systemic immunosuppressants in people with psoriasis may confer greater risk of adverse COVID-19 outcomes but data are limited. OBJECTIVE: Characterize the course of COVID-19 in psoriasis and identify fa... Read More about Factors associated with adverse COVID-19 outcomes in patients with psoriasis: insights from a global registry-based study.

Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic. (2020)
Journal Article
Mahil, S., Yiu, Z., Mason, K., Dand, N., Coker, B., Wall, D., …Smith, C. (in press). Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic. British Journal of Dermatology, 183(2), 404 - 406. https://doi.org/10.1111/bjd.19161

'No abstract'

Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). (2020)
Journal Article
Yiu, Z., Mason, K., Hampton, P., Reynolds, N., Smith, C., Lunt, M., …Warren, R. (2020). Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). British Journal of Dermatology, 183(2), 294 - 302. https://doi.org/10.1111/bjd.18981

BACKGROUND: Real-world biologic drug survival is an important proxy measure for effectiveness. Predictors of drug survival may help patients with psoriasis choose between biologic therapies. OBJECTIVES: (i) To assess the relative drug survival of... Read More about Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)..

Factors associated with hospitalization due to COVID‐19 in patients with psoriasis: insights from a global registry (2020)
Presentation / Conference
Mahil, S., Dand, N., Mason, K., Yiu, Z., Tsakok, T., Meynell, F., …Smith, C. (2020, July). Factors associated with hospitalization due to COVID‐19 in patients with psoriasis: insights from a global registry. Paper presented at British Association of Dermatologists 100th Annual Meeting, Virtual

Psoriasis is a common immune‐mediated inflammatory skin disease with frequent multimorbidity, and immunosuppressants are the mainstay of treatment in moderate‐to‐severe disease. An understanding of the impact of COVID‐19 on individuals with psoriasis... Read More about Factors associated with hospitalization due to COVID‐19 in patients with psoriasis: insights from a global registry.

Clinical Impact of Antibodies against Ustekinumab in Psoriasis: An Observational, Cross-Sectional, Multicenter Study (2020)
Journal Article
Loeff, F. C., Tsakok, T., Dijk, L., Hart, M. H., Duckworth, M., Baudry, D., …Warren, R. B. (2020). Clinical Impact of Antibodies against Ustekinumab in Psoriasis: An Observational, Cross-Sectional, Multicenter Study. Journal of Investigative Dermatology, 140(11), 2129-2137. https://doi.org/10.1016/j.jid.2020.03.957

Ustekinumab is an effective treatment for psoriasis, but response varies between patients. The formation of anti-drug antibodies (ADAs) may explain part of this variation by reducing the free ustekinumab level. Currently, published analyses of the cl... Read More about Clinical Impact of Antibodies against Ustekinumab in Psoriasis: An Observational, Cross-Sectional, Multicenter Study.

Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review (2020)
Journal Article
Al-Janabi, A., Foulkes, A. C., Mason, K., Smith, C. H., Griffiths, C. E. M., & Warren, R. B. (2020). Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review. Journal of the European Academy of Dermatology and Venereology, 34(7), 1440-1448. https://doi.org/10.1111/jdv.16246

The use of biologic therapies for the treatment of chronic plaque psoriasis has been linked to the development of atopic eczema, amongst other cutaneous adverse events. This can cause diagnostic confusion and create difficulty in the management of pa... Read More about Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review.

A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis. (2019)
Journal Article
Yiu, Z., Mason, K., Barker, J., Hampton, P., McElhone, K., Smith, C., …Burden, A. (in press). A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis. British Journal of Dermatology, 181(6), 1265 - 1271. https://doi.org/10.1111/bjd.17849

BACKGROUND: Patients recruited in randomized controlled trials (RCTs) for biologic therapies in psoriasis are not fully representative of the real-world psoriasis population. OBJECTIVES: Firstly, to investigate whether patient characteristics are ass... Read More about A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis..

Risk of major cardiovascular events in adult patients with psoriasis treated with biologic therapies or methotrexate: Cohort study in the British Association of Dermatologists Biologic Interventions Register (BADBIR) (2019)
Journal Article
Rungapiromnan, W., Mason, K., Lunt, M., McElhone, K., Burden, A., Rutter, M., …Study Group, B. (2020). Risk of major cardiovascular events in adult patients with psoriasis treated with biologic therapies or methotrexate: Cohort study in the British Association of Dermatologists Biologic Interventions Register (BADBIR). Pharmacoepidemiology and Drug Safety, 34(4), 467 - 467. https://doi.org/10.1111/jdv.16018

Background The cardiovascular safety profile of biologic therapies used for psoriasis is unclear. Objectives To compare the risk of major cardiovascular events (CVE s; acute coronary syndrome, unstable angina, myocardial infarction and stroke) i... Read More about Risk of major cardiovascular events in adult patients with psoriasis treated with biologic therapies or methotrexate: Cohort study in the British Association of Dermatologists Biologic Interventions Register (BADBIR).

All Outputs (73)